Management of Comorbid Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and Anxiety in Pediatric PMHNP Practice

作者：Basnet D, Beauvois L · 发表于：Journal of psychosocial nursing and mental health services · 年份：2026 · DOI：10.3928/02793695-20260609-03 · 研究领域：Attention Deficit Disorder with Hyperactivity、Autism Spectrum Disorder、Guanfacine、Psychiatric Nursing、Anxiety Disorders、Adrenergic alpha-2 Receptor Agonists、Humans、Child、Comorbidity、Delayed-Action Preparations

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by deficits in social communication and restricted, repetitive behaviors, frequently accompanied by comorbid psychiatric conditions, such as anxiety and attention-deficit/hyperactivity disorder. Symptom overlap complicates diagnosis, whereas the absence of tailored clinical guidelines contributes to variable practices and the risk of over- and undertreatment. The current article examines the efficacy and safety of guanfacine extended-release (GXR) for the treatment of hyperactivity, impulsivity, and associated behavioral symptoms in children with ASD and comorbid psychiatric conditions. Current evidence supports GXR as an effective nonstimulant option with a tolerable safety profile, particularly for children with co-occurring anxiety or sleep disturbance or those who are poor candidates for stimulant therapy. Careful titration and ongoing monitoring remain essential given this population's heightened sensitivity to adverse effects. For psychiatric-mental health nurse practitioners, these findings underscore the importance of individualized, family-centered care; ASD-specific assessment; and interdisciplinary collaboration. Ethical prescribing, ongoing clinical monitoring, and meaningful caregiver engagement are essential to optimizing outcomes and enhancing quality of life for children with ASD and comorbid psychiatric conditions.